ArticleOncology letters2020
Article in Oncology letters, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.
- CanBMJ open · 2021Pooled it
- Metabolic tumor volume onTranslational lung cancer research · 2025Article
- Application ofDiagnostics (Basel, Switzerland) · 2025Article
- Correlation of 18F-FDG PET/CT SUV with Colon Cancer Aggressiveness and Superior Diagnostic Performance Over CT for Lymph Node Metastasis: A Retrospective Analysis.Cancer management and research · 2025Article
- Biomarker and Prognostic Value of Super-ARMS Detection for EGFR Mutation in Advanced NSCLC.OncoTargets and therapy · 2025Article
- Clinical impact of pleural fluid carcinoembryonic antigen on therapeutic strategy and efficacy in lung adenocarcinoma patients with malignant pleural effusion.The Korean journal of internal medicine · 2024Article
- Driver gene alterations in NSCLC patients in southern China and their correlation with clinicopathologic characteristics.Frontiers in genetics · 2024Article
- Association between cigarette smoking history, metabolic phenotypes, andJournal of thoracic disease · 2023Article
- Maximakinin reduced intracellular CaHypertension research : official journal of the Japanese Society of Hypertension · 2023Article
- New research progress on 18F-FDG PET/CT radiomics for EGFR mutation prediction in lung adenocarcinoma: a review.Frontiers in oncology · 2023Review
- Association between squamous cell carcinoma antigen level and EGFR mutation status in Chinese lung adenocarcinoma patients.Journal of clinical laboratory analysis · 2022Article
- Clinical Utility of Plasma Cell-Free DNA EGFR Mutation Analysis in Treatment-Naïve Stage IV Non-Small Cell Lung Cancer Patients.Journal of clinical medicine · 2022Article
- A Review of the Correlation Between Epidermal Growth Factor Receptor Mutation Status andFrontiers in oncology · 2022Review
- PET/CT Radiomic Features: A Potential Biomarker for EGFR Mutation Status and Survival Outcome Prediction in NSCLC Patients Treated With TKIs.Frontiers in oncology · 2022Article
- Clinicopathologic Features and Molecular Biomarkers as Predictors of Epidermal Growth Factor Receptor Gene Mutation in Non-Small Cell Lung Cancer Patients.Current oncology (Toronto, Ont.) · 2021Review
- Serum carcinoembryonic antigen elevation in benign lung diseases.Scientific reports · 2021Article
- Biological Significance ofInternational journal of general medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) contribute to an increased response rate, compared with chemotherapy, in patients with inhibitor-sensitive EGFR mutations. The present study evaluated the association between the maximum standardized uptake value (SUV
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.